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Abstract 
Background 
Recruiting participants to multicentre, community-based trials is a challenge. This case study 
describes how this challenge was met for the BeWEL trial, which evaluated the impact of a 
diet and physical activity intervention on body weight in people who had had pre-cancerous 
bowel polyps. 
Methods 
The BeWEL trial was a community-based trial, involving centres linked to the Scottish 
National Health Service (NHS) colorectal cancer screening programme. BeWEL had a 
recruitment target of 316 and its primary recruitment route was the colonoscopy clinics of the 
Scottish Bowel Screening Programme. 
Results 
BeWEL exceeded its recruitment target but needed a 6-month no-cost extension from the 
funder to achieve this. The major causes of delay were lower consent rates (49% as opposed 
to 70% estimated from earlier work), the time taken for NHS research and development 
department approvals and the inclusion of two additional sites to increase recruitment, for 
which there were substantial bureaucratic delays. A range of specific interventions to increase 
recruitment, for example, telephone reminders and a shorter participant information leaflet, 
helped to increase the proportion of eligible individuals consenting and being randomized. 
Conclusions 
Recruitment to multicentre trials is a challenge but can be successfully achieved with a 
committed team. In a UK context, NHS research and development approval can be a 
substantial source of delay. Investigators should be cautious when estimating consent rates. If 
consent rates are less than expected, qualitative analysis might be beneficial, to try and 
identify the reason. Finally, investigators should select trial sites on the basis of a formal 
assessment of a site’s past performance and the likelihood of success in the trial being 
planned. 
Trial registration 
Current Controlled Trials ISRCTN53033856 
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colorectal cancer, multicentre trial, recruitment 
Background 
Randomized controlled trials (RCTs) are the gold standard for the evaluation of the 
effectiveness and safety of healthcare interventions, particularly because they protect against 
selection bias [1]. However, recruiting health professionals and patients to RCTs can be 
extremely difficult: studies of recruitment suggest that at least 45% of studies fail to achieve 
their recruitment targets, although those involving a clinical trials unit do somewhat better, 
with 65% (20/31) of trials recruiting to target [2,3]. This may result in an underpowered trial, 
which, in turn, may lead to non-significant results that nevertheless do not rule out the 
possibility of important benefits. Recruitment failings increase the risk that an effective 
intervention will be abandoned before its true value is appreciated, or can lead to delays in 
demonstrating the benefits of an intervention while further trials are conducted. Poor 
recruitment (and retention) may also lead to a trial being extended, increasing costs. 
Investigators use many interventions to improve recruitment [4-6] but evidence regarding the 
likely effect of these interventions is often unclear. 
Community-based studies face particular challenges because of the dispersed nature of both 
the recipients of services and the professionals delivering the services [7]. Recruitment efforts 
can be hampered by actual or perceived demands of transportation, unfamiliarity with study 
sites for appointments, and inflexible appointment times within working hours. The Cochrane 
review of interventions to improve recruitment has a planned subgroup analysis comparing 
studies by setting (for example, community versus secondary care recruitment) but has not 
found enough community and primary care studies to include in the analysis, despite 
including a total of 45 studies [5]. More rigorous evaluations of recruitment interventions are 
needed, especially in community and primary care. 
The BeWEL study was a multicentre RCT evaluating the impact of a diet and physical 
activity intervention on body weight in people who have had pre-cancerous bowel polyps [8]. 
The relationship between diet, physical activity, excess weight and increased risk of 
colorectal cancer (and other chronic disease) is well described [9] and the National Health 
Service (NHS) colorectal cancer screening programme offers a timely opportunity to offer 
intervention support. The aim was to recruit 316 eligible participants over a period of 12 
months. However, obtaining the necessary research governance and ethical approval went 
more slowly than expected, which quickly led to a shorter time frame to meet the recruitment 
target. This paper aims to critically review the methods employed to overcome this challenge 
and so provide insight into the implications for future trials. 
Methods 
BeWEL’s sample size was calculated on the basis of a clinically important weight loss at 12 
months of 7%, which at 80% power meant that 133 participants would be required to 
complete each arm of the study. The target of 7% weight loss at 12 months was chosen as this 
has been found to be effective for diabetes prevention [10]. Allowing for a dropout rate of 
16%, as seen in the similar Bowel Health to Better Health (BHBH) study [11], meant that 158 
participants were required for each arm, giving a recruitment target of 316. Individuals were 
eligible for the trial if they were aged 50 to 74 years with a BMI greater than 25 kg/m2 and 
had been found to have benign adenomas after a screening colonoscopy done as part of the 
Scottish Bowel Screening Programme (http://www.bowelscreening.scot.nhs.uk). Individuals 
also needed to have been physically able to undertake the trial’s exercise requirements and to 
be able to provide informed consent. Individuals were not eligible for the trial if they had a 
normal colonoscopy, malignant lesion or insulin dependent diabetes. 
The participants for BeWEL were recruited through the colonoscopy clinics of the Scottish 
Bowel Screening Programme. The planned recruitment strategy [8] was as follows: 
1. A brief letter about BeWEL from the colorectal cancer surgeon, enclosed with the 
screening results, endorsing the study and encouraging the recipient to read an 
information sheet that would be sent by the study team within two weeks. 
2. An information leaflet, letter of invitation, reply slip and pre-paid envelope was then sent 
by the study team. 
3. Those indicating that they would like to take part were screened for eligibility over the 
telephone by a research nurse. Eligible individuals were then invited to attend a study 
centre to provide consent and undergo baseline measures. 
4. Non-responders were sent a reminder after two weeks, which included the information 
leaflet, letter of invitation, reply slip and pre-paid envelope. 
Based on this plan and an estimated positive response rate of 70%, based on a previous study 
of diet and physical activity [11], three colonoscopy clinics were recruited to take part in the 
trial, one each in the Tayside, Forth Valley, and Ayrshire and Arran regions of Scotland. 
Monthly trial management group meetings monitored recruitment using site-specific 
CONSORT diagrams, as well as a CONSORT diagram for the trial as a whole. 
Approvals 
BeWEL was approved by the Tayside Committee on Medical Research Ethics (Committee 
B), REC reference 10/S1402/34 and received research and development approval from NHS 
Ayrshire and Arran, NHS Forth Valley, NHS Greater Glasgow and Clyde and NHS Tayside. 
Results 
A diagram of participant flow is given in Figure 1. A total of 997 letters of invitation were 
sent between November 2010 and April 2012 (17 months) to individuals who had undergone 
colonoscopy following a positive faecal occult blood test as part of the Scottish Bowel 
Screening Programme, had a diagnosis of adenoma confirmed by histopathology and were 
aged 50 to 74 years. To the best of our knowledge, these were all patients screened in the 
participating Health Boards for whom an adenoma was detected. Of these, 492 replied 
positively (49%) but 108 (22%) were ineligible as their BMI was less than 25 kg/m2, 42 (9%) 
declined to proceed after receiving detailed information of the requirements and 13 (3%) 
replied after the recruitment period had ended. Thus, 329 patients went on to be randomized 
(33%), exceeding the target recruitment of 316. Retention was higher than estimated, leading 
to a larger pool for analysis (305) than was required in the sample size calculation (266) 
(Table 1). 
Figure 1 Participant flow through the trial. Where a number is marked as an estimate, this 
is the number we used pre-trial for planning. * Participants attended the 12-month interview. 
Table 1 Estimates used in planning recruitment and the numbers actually achieved in 
the trial 
Recruitment assumption Estimate Actual 
Loss to follow-up 16%a 7% 
Consent rate 70%a 49% 
Recruitment target 316 329 
aData from [11]. 
Although the recruitment target was met, this was not achieved without modifying the 
original recruitment plan. The strategies introduced are listed in Table 2. Upon the initial 
delayed start to recruitment, the first modification was made, which was to approach new 
sites for recruitment and begin the approvals process. By month three, the positive response 
and randomization rates were 31% and 17%, respectively, indicating a need for further efforts 
to improve recruitment. Strategies 2 to 8 were then introduced. 
Table 2 Recruitment strategies employed in the BeWEL trial 
Strategy number Strategy Date started (Month number) 
1 New sites approached for study inclusion. November 2010 (Month 1) 
2 Research nurse telephones non-responders (suggested by [4,5]). January 2011 (Month 3) 
3 BMI cut-off at telephone screening reduced to 24 kg/m2 to avoid excluding 
participants who had underestimated their BMI. Such participants were invited to 
visit the research centre to have their eligibility confirmed. 
January 2011 (Month 3) 
4 Frequency of visits by the trial manager to research nurses and on-site NHS staff 
increased to monthly. 
May 2011 (Month 7) 
5 Brief participant information leaflet introduced and printed on high-quality paper 
with NHS logos. This was sent with the invitation letter in hand-written envelopes 
(suggested by [12,13]). 
June 2011 (Month 8) 
6 The local consultants’ names and their endorsement of the study were added to the 
invitation letter. 
June 2011 (Month 8) 
7 Eligible participants unable to travel to a study site for assessments were offered 
home visits. 
July 2011 (Month 9) 
8 Letters of congratulation were sent to sites for good recruitment. November 2011 (Month 13) 
Strategy 1: New sites approached for study inclusion 
Research staff in the UK who do not have contracts with the NHS need a document called a 
‘research passport’ before they can contact NHS patients or access their data (see 
http://www.ukcrc.org/regulationgovernance/researchpassport/). Obtaining these documents 
took longer than anticipated, meaning that recruitment to BeWEL at all sites began three 
months late. Therefore, in November 2010, an initial approach was made to Gartnavel 
General Hospital, NHS Greater Glasgow and Clyde (GG&C), to discuss the BeWEL study 
and seek approvals. By March 2011, a further site in Fife had also been approached but the 
GG&C site was still awaiting NHS research and development (R&D) approvals. In April 
2011, the Trial Steering Committee met and suggested that the site in Fife be kept on hold 
and the study be extended for a short period to meet its recruitment target rather than having 
to go through the time-consuming permissions process. Subsequently, an additional GG&C 
site (Victoria Infirmary) became involved, through local consultant interest. Both additional 
sites were positive and the process of gaining ethical approval was smooth. The process of 
gaining R&D approvals and issuing research passports, as well as delays caused through 
clinicians needing to provide paperwork, meant that it took seven months and considerable 
effort from the trial team to gain all the relevant permissions for Gartnavel General Hospital 
(submitted November 2010 and approved July 2011). The second of the two sites, Victoria 
Infirmary, agreed to take part in September 2011 but obtaining permissions took until 24 
January 2012, with just four months recruitment time remaining. By the end of recruitment, 
only five participants were recruited through the two Glasgow sites. 
Strategy 2: Research nurse telephones non-responders 
There is high-quality evidence that telephone reminders to non-responders increase trial 
recruitment [4,5] and telephone reminders were added to the protocol after the first three 
months of recruitment. Two weeks after the reminder invitations were sent out, the research 
nurses telephoned individuals who had not responded, up to a maximum of three times over a 
two-week period. This required a change to the invitation letter to make it clear that the trial 
team would telephone non-responders, and a substantial amendment to be submitted to the 
ethics committee for approval (submitted 21 December 2010 and approved 24 January 2011). 
Telephone reminders were time consuming but led to the recruitment of an additional 14 
participants (Table 3). 
Table 3 Recruitment return of telephone reminders to non-responders to a postal 
reminder invitation 
Site identifier: Health 
Board 
Number sent 
reminder letter 
Number of non-
responders to reminder 
letter (%) 
Number of non-
responders 
telephoned (%) 
Number not 
responding to any 
calls (%) 
Number 
recruited after 
call (%) 
Site 1: Tayside 141 70 (50) 27 (39) 4 (15) 0 (0) 
Site 2: Forth Valley 103 52 (50) 40 (77) 18 (45) 5 (13) 
Site 3: Ayrshire & Arran* 67 33 (49) 28 (85) 2 (7) 9 (32) 
Site 4: Greater Glasgow 7 7 (100) 3 (44) 0 (0) 0 (0) 
Site 5: Greater Glasgow 2 1 (50) 0 (0) 0 (0) 0 (0) 
Total 320 163 (51) 98 (60) 24 (24) 14 (14) 
*Owing to a misunderstanding, Ayrshire and Arran only started to follow the telephone reminder protocol in July 2011, not 
January 2011, as at the other sites. 
Strategy 3: BMI cut-off at telephone screening reduced to 24 kg/m2 
It is widely documented that there is a tendency for height to be overestimated and weight to 
be underestimated, such that self-reported BMI is often underestimated, especially in men 
[14]. The trial management group therefore agreed that potential participants who self-
reported their BMI to be 24 to 25 kg/m2 be invited into the study centre to have their 
eligibility checked. This resulted in screening an additional 15 individuals, of whom ten were 
eligible and all were recruited. 
Strategy 4: Frequency of visits by the trial manager to research nurses and 
on-site NHS staff increased to monthly 
The trial manager was in daily email or telephone contact with site research nurses to offer 
support as necessary. The trial management group initiated monthly visits to sites by the trial 
manager to offer face-to-face support to research teams and to maintain the visibility of the 
trial at the sites. In total, there were 17 visits to Ayrshire and Arran, 15 to Forth Valley and 
six to GG&C. The situation for Tayside was somewhat different, since the trial manager was 
based at the same hospital and there was therefore very regular contact between the trial 
manager and research nurse at this site. Although the support and endorsement of consultants 
at each site was essential, it was also important to establish good working relationships with 
all referring and administrative staff. An administrative assistant was also employed to 
support research nurses and lifestyle counsellors with the day-to-day running of the trial. 
Although supporting these relationships was considered essential for the success of BeWEL, 
there is very little published evidence regarding their effect on recruitment [4-6]. A single 
study has evaluated the effect of site initiation visits and found that they did not increase 
recruitment [15]. That study’s host trial was terminated early and the effect of repeat visits on 
recruitment could not be studied. 
Strategy 5: Brief participant information leaflet introduced and printed on 
high-quality paper with NHS logos 
The full participant information leaflet (PIL) was an eight-page document covering all 
aspects of the trial, including mandatory sections that were required for ethical approval. 
Although the evidence for trial recruitment benefit (or harm) for short versus long PILs is 
unclear [4,5], there is evidence that shorter questionnaires lead to higher response rates 
[12,13]. A brief-two page PIL was also prepared to be sent two weeks after the initial 
invitation letter. In addition, the NHS logo was added to both the brief and full PILs, to take 
advantage of positive feelings about the NHS screening service that were reported during 
BeWEL’s formative work. Finally, “Please note this study does not involve any further bowel 
examination,” was added to the brief PIL, as a number of participants had asked whether they 
had to have another colonoscopy as part of the study. Ethical approval was obtained to 
introduce the brief PIL on the understanding that the full leaflet would be provided to 
potential participants before consent was obtained. Introducing the brief PIL required 
submission of a substantial amendment to the ethics committee for approval (submitted 23 
June 2011 and approved 29 June 2011). 
Strategy 6: The local consultants’ names and their endorsement of the study 
were added to the invitation letter 
The invitation letter was amended to show the consultant’s name and his endorsement of the 
study. This decision was based on a belief that potential participants would be more likely to 
respond to a letter signed by someone they recognised. There is no compelling evidence for 
such an effect [13], although the possibility of a small benefit is not ruled out completely. The 
strategy was, however, simple and cheap to implement. This required a substantial 
amendment to be submitted to the ethics committee for approval (submitted 23 June 2011 and 
approved 29 June 2011). 
Strategy 7: Eligible participants unable to travel to a study site for 
assessments were offered home visits 
Some participants in Ayrshire and Arran and in Tayside, both large and rural areas, found it 
difficult to travel to a study site for assessments. To address this, the protocol was amended to 
include the possibility of home visits by research nurses for participants in any of the areas 
taking part in BeWEL. Ten participants opted to have home assessments, all from Tayside. 
Adding home visits required a substantial amendment to be submitted to the ethics committee 
for approval (submitted 29 June 2011 and approved 14 July 2011). 
Strategy 8: Letters of congratulation to sites for good recruitment 
A total of six letters of congratulation were sent out to participating sites (three to Tayside, 
three to Ayrshire and Arran) between January and June 2012. The sites were commended for 
their continued support for the study and told how many of their referrals were eligible and 
had given signed consent to participant in the BeWEL study. 
Combined impact of the additional recruitment strategies on accrual 
The first and most lengthy recruitment strategy instigated was the addition of two further 
sites. Figure 2 shows the actual cumulative monthly recruitment along with planned 
recruitment and estimated monthly recruitment if the two Glasgow sites had begun recruiting 
in March 2011 (four months after the start of the trial) under two scenarios. In the first 
scenario (dotted line), the two Glasgow sites have a combined recruitment equivalent to the 
average of the monthly rates at the three other sites. In the second scenario (dashed line), each 
of the Glasgow sites recruits at a rate equivalent to the average of the monthly rates at the 
other three sites (see Table 4). In the former scenario, the BeWEL trial would have reached 
its recruitment target around three months earlier, in February 2012. In the latter scenario, the 
recruitment target would have been reached six months earlier, in November 2011, or just 
one month behind the original schedule. Finally, the percentage of eligible individuals who 
consented to take part and went on to be randomized increased steadily throughout the trial 
from 17% in Jan 2011 to 33% in May 2012, when the trial reached its recruitment target 
(Figure 3). 
Figure 2 Planned, actual and estimated total monthly recruitment. The estimated 
monthly recruitment rate is based on two scenarios. Scenario 1 (dotted line): the two Glasgow 
sites had a combined monthly recruitment rate equivalent to the average of the monthly rates 
at the three other sites. Scenario 2 (dashed line): the two Glasgow sites each recruited at a 
similar rate to the other three sites. 
Table 4 Monthly recruitment figures by site, including estimated monthly recruitment 
at Greater Glasgow under two scenarios 
Month Ayrshire 
& Arran 
Forth 
Valley 
Tayside Actual, 
Greater 
Glasgow 
Estimated, 
Greater 
Glasgow 
(scenario 1) 
Estimated, 
Greater 
Glasgow 
(scenario 2) 
Actual total 
monthly 
recruitment 
Estimated 
total monthly 
recruitment 
(scenario 1) 
Estimated 
total monthly 
recruitment 
(scenario 2) 
November 2010 0 0 1 0 0 0 1 1 1 
December 2010 0 1 0 0 0 0 1 1 1 
January 2011 2 7 3 0 0 0 12 12 12 
February 2011 6 11 6 0 0 0 23 23 23 
March 2011 3 6 10 0 6 13 19 25 32 
April 2011 3 7 1 0 4 7 11 15 18 
May 2011 3 7 7 0 6 11 17 23 28 
June 2011 5 4 8 0 6 11 17 23 28 
July 2011 9 6 8 0 8 15 23 31 38 
August 2011 9 5 5 0 6 13 19 25 32 
September 2011 7 8 3 0 6 12 18 24 30 
October 2011 11 5 7 0 8 15 23 31 38 
November 2011 6 7 6 1 6 13 20 25 32 
December 2011 9 2 21 0 4 8 132 17  
January 2012 3 1 4 0 3 5 8 11  
February 2012 7 4 9 0 7 13 20 27  
March 2012 7 6 10 0 8 15 23   
April 2012 13 10 9 0 11 21 32   
May 2012 18 3 4 4 8 17 29   
Total       329 314 313 
Scenario 1, the two Glasgow sites on board in March 2011 and have a combined recruitment equivalent to the average of the 
monthly rates at the three other sites; scenario 2, the two Glasgow sites on board in March 2011 and recruit at a rate 
equivalent to the average of the monthly rates at the other three sites. In scenario 1, BeWEL would have reached its target 
about three months earlier; in scenario 2, the target would have been met about six months earlier. 
Figure 3 The proportion of eligible individuals who were randomized each month. 
Discussion 
The BeWEL trial met its recruitment target. However, despite close monitoring and 
considerable resources and effort being targeted at recruitment, the trial still required a six 
month no-cost extension from the funder to meet this target. Although the funder provided no 
additional funding, extending the trial by six months was possible because of flexibility 
shown by contracted staff and because core-funded and other departmental staff contributed 
more time. By three months into the trial, it was clear that recruitment was not going as 
planned and a series of interventions to increase recruitment were implemented, including 
interventions with evidence of benefit from systematic reviews (for example, telephone 
reminders to non-respondents [4,5]). Whilst these probably helped, as demonstrated in Figure 
3, which shows a steady increase in the proportion of eligible individuals consenting and 
being randomized, there was no magic-bullet recruitment intervention that led to a step 
change in recruitment rates. Some interventions required substantial effort, such as repeated 
telephone attempts to contact participants and visiting remote rural locations. It is also clear 
that, as others have reported [16], recruitment in the first couple of months or so is indicative 
of later recruitment unless action is taken. To have assumed that slow recruitment was merely 
trial growing pains rather than a problem to be dealt with immediately would have been a 
mistake. 
There are essentially two issues at the heart of BeWEL’s recruitment challenges: 
1. Estimating the number of potentially eligible participants who will agree to take part; 
2. Introducing extra recruitment sites. 
Estimating the number of potentially eligible participants who will agree to 
take part 
The estimate of 200 patients diagnosed each year at the three original sites turned out to be 
accurate but the proportion who were eligible was 75%, not 81%, as estimated. This 
relatively small difference was then compounded by eligible participants who changed their 
mind after initially saying yes (42, or 9%) to participation, which was not expected. 
A greater problem though, was the consent rate, which was 49%, not the estimated 70%. 
Formative qualitative research was conducted to help check the acceptability of the 
intervention concept and to refine methods before recruitment started [17]. This gave insight 
into how the initial approach to patients could be improved; for example, that colorectal 
cancer health professionals act as advocates for the study and repeat its endorsement by the 
lead clinician, suggestions that were incorporated into the recruitment strategy for BeWEL. 
One important finding from the formative research was that patients had little understanding 
of the potential link between adenoma risk and their own health behaviour, and consequently 
struggled to see the relevance of an invitation to participate in a lifestyle-change study. This 
was reinforced by the tendency of health professionals during and after adenoma treatment to 
adopt a reassuring tone that downplayed risk. The ‘all-clear’ messages that patients picked up 
from written and verbal communication after their adenoma operation implied a ‘clean bill of 
health’ and indicated that there was nothing about their lifestyle requiring modification. 
Although efforts were made in the trial recruitment process to address this problem by 
making clearer the potential links between adenoma risk and lifestyle behaviour, it is possible 
that the link was still not sufficiently salient or believable for some patients, and that this may 
have contributed to reluctance to participate in the study. 
The estimated consent rate of 70% was based on the BHBH study [11], a trial similar to 
BeWEL. The BHBH study reported two consent rates: an overall rate of 51% and an ‘initial’ 
rate of 68%; the latter rate was the rate seen before a second Dundee-based trial started 
recruiting from the same patient pool. The 68% rate seemed to be a reasonable choice for 
BeWEL, given the clear link between the fall in the BHBH study consent rate and the start of 
recruitment by the second trial. As we found later, the overall BHBH consent rate would have 
been a better bet. Additionally, although the BHBH study was similar to BeWEL there were 
two key differences. The first was that the BeWEL intervention placed more demands on 
patients, requiring a 12-month commitment from participants rather than three. The second 
was that weight management was included in BeWEL but not in the earlier trial, which again 
might have deterred some from participating. Although most of the BeWEL participants who 
were interviewed at the end of the program found the 12-month duration and inclusion of 
weight management acceptable and not too onerous or intrusive, these were of course patients 
who had agreed to participate; we do not know how many were put off coming forward in the 
first place by the perceived demands of participation in the study. 
There are a couple of key lessons in this experience. Firstly, how should investigators 
estimate consent rates? One simple approach would be for investigators to estimate no more 
than 50% unless they have experience of higher consent from several studies in the same 
population being recruited in the same setting. This appears rather arbitrary but a study of 
recruitment in 207 breast cancer trials calculated the number needed to recruit one additional 
participant for the 69 trials that provided sufficient information to do the calculation and the 
result was remarkably consistent, with a median of two individuals being approached for 
every person recruited [18]. Gross et al. [19] found a median of 1.8 (range, 1 to 68) for their 
study of 172 trials, whereas Toerien et al. [20], in their study of 133 trials, found that 
investigators assessed a median of 230% of their target number. A consent rate estimate of 
50% is perhaps a reasonable rule of thumb in the absence of compelling evidence upon which 
to base it. More compelling evidence would comprise data from two or more studies that 
have recruited the same population, in the same setting, using the same sort of staff, for the 
same sort of intervention and all within recent history. Even with these data, investigators 
would need to make evidence-informed, judgement-based decisions about the similarity 
between earlier recruitment contexts and their own. It would be possible to put confidence 
intervals around consent rates from other studies, including pooled estimates, but it is context, 
not statistical uncertainty, that is likely to be the main driver of variability in consent rates. It 
is far from clear that taking the lower bound of the confidence interval would provide more 
reassurance than would be the case if investigators (ourselves included) were simply more 
conservative when estimating consent rates, and many other parameters besides. The best 
approach to consent rate planning remains in-context pilot work prior to the full-scale trial. 
The second lesson was that once it became apparent that fewer patients were consenting to 
take part, one additional strategy would have been to conduct a second stage of qualitative 
research. This need not have been a major exercise, as one or two focus groups or a small 
number of individual interviews would have sufficed. This second stage could have focused 
on exploring the views of those patients who expressed an initial interest but then did not 
follow through, to see whether any of the reasons for reluctance were amenable to action. 
This kind of research exercise has been used to explore how patients interpret and respond to 
informed consent materials provided in clinical trials [21]. ‘Consumer research’ of this sort 
could play a valuable role throughout the development and implementation of an intervention 
in remedying problems as they occur. Indeed, given the commonplace nature of trial process 
problems, investigators would do well to build in the possibility of adding rapid, response-
mode qualitative work to their initial ethical and other approval submissions. 
Bringing on extra sites 
There were 13 months between the trial management team’s first discussion with a Glasgow 
site and the first Glasgow recruit. At the end of the trial, the two sites together had been able 
to recruit only five participants. Conjecture as to what might have been is, perhaps, of limited 
utility but had the two extra sites both recruited at a similar rate to the other sites (Scenario 2 
in Figure 2 and Table 4), then the trial would have met its target only one month behind the 
original recruitment schedule. In the three original sites, considerable negotiation had been 
undertaken well before the funding bid had been submitted, and again after the funding award 
announced, highlighting the time required to match sites to study requirements. Thus, by the 
time the study started, the preparatory work at each site had been undertaken. This was not 
the case in the two Glasgow sites, where many months were taken up as a consequence of 
NHS R&D departmental work practices being different from other sites, a situation made 
worse by the loss of the trial manager to take up another post during the latter stage of 
funding negotiations. Moreover, the anticipated time for recruitment from these two sites was 
not fully factored in to the revised recruitment plan. 
This experience points towards a number of suggestions linked to site selection: 
• Identify more sites than are expected based on pre-trial assumptions as an insurance policy 
against those assumptions proving incorrect. The number of extra sites will depend on how 
confident investigators are about their pre-trial assumptions. If all, or some of the 
approvals for these sites can be obtained up-front (that is, before they are actually needed), 
so much the better. 
• Formally assess all sites for suitability for the trial. The trial team should use a checklist of 
key features of a site that they believe are essential for successful participation. The team 
could develop its own checklist, or modify an existing one (for examples, see Warden et 
al. [22]). 
• Sites that do not meet the requirements listed on the checklist should be reviewed to 
determine whether measures could be put in place by the trial team to support the site in 
meeting the checklist criteria. If not, the site should not be considered for the trial. 
Clearly, no site is ideal for all trials but there is growing agreement that sites should be 
selected based on a formal assessment of their past performance and the likelihood of success 
in the trial being planned [22-24]. As Shah pointed out in a recent roundtable discussion of 
heart failure trials [23]: 
‘There is a peculiar paradox that exists in trial execution - we perform clinical 
trials to generate evidence to improve patient outcomes; however, we conduct 
clinical trials like anecdotal medicine: (1) we do what we think works; (2) we 
rely on experience and judgement and (3) limited data to support best 
practices.’ 
What features of a site might predict its future performance in a given trial is worthy of more 
research but some features that may be relevant [22-24] include: 
• Previous experience with multicentre trials; 
• Familiarity of operating a trial protocol and the closeness of the trial protocol to the 
clinical procedures currently in place at the site; 
• Familiarity with the local approvals process; 
• Previous recruitment performance; 
• Case mix and access to eligible participants; 
• Availability of resources such as research nurses, study coordinators, research pharmacists, 
administrators; 
• Lack of competing demands that would hinder the site’s ability to fully engage with the 
trial. 
Future research could focus on systematically reviewing the trial management literature for 
studies in order to evaluate formal site-selection methods and develop prediction rules and 
metrics that can be used for site selection. 
Conclusions 
Recruitment plans rarely survive contact with actual participants [2]. Though challenging, 
recruitment to multicentre trials can be successfully achieved with a committed team. In a 
UK context, NHS R&D management approval can be a substantial source of delay, whilst 
obtaining ethical approval is a much smoother process. Investigators should be cautious when 
estimating consent rates and it may be beneficial to do qualitative work during the trial if 
consent rates are less than expected, to try and identify the reason. Finally, investigators 
should select trial sites on the basis of a formal assessment of a site’s past performance and 
the likelihood of success in the trial being planned. 
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